Sickle Cell Patient Treatment

According to NHBLI (2008), sickle cell anemia is one of the most common genetic diseases in the United States, affecting more than 100,000 people. Anyone suffering from sickle cell anemia must seek advice from experts and treatments to combat the disease, but recently these patients are not treated in the medical field. Therefore, further research and funding will be needed in the future to provide optimal treatment and effective treatment for patients with sickle cell anemia. Studies have shown that lack of treatment for patients with sickle cell disease, drugs are rare and poor, which medically ignore this population.

Treatment of sickle cell anemia varies. There is currently no cure for sickle cell anemia. However, there are many treatments for sickle cell anemia that can reduce the frequency and severity of pain and improve the quality of life for patients. Early detection of sickle cell anemia can save human life. Newborn screening can be done before the baby leaves the hospital. Infants found to have sickle cell disease can enter immediate pediatric care program. If a doctor frequently see a baby and her parents are trained to take care of a sickle-shaped red blood cell baby, many problems can be avoided or discovered at an early stage. In special cases, transfusion or bone marrow transplantation may be necessary.

Sickle cell disease is the most common hereditary monogenic disorder. Approximately 90,000 people in the United States suffer from sickle cell disease, and more than 275,000 infants worldwide suffer from this disease. 1,2 sickle cell disease is the first disease to discover the molecular basis. - Globin (Glu 6 Val) derived from single base substitution (A → T) of the first exon of the human β A globin gene (HBB) was discovered in 1956. 3 Scorpion Hemoglobin (HbS) Polymerizes During Deoxygenation Reduces Deformable Red Cells There is a risk of severe painful vascular occlusion, resulting in irreversible organ damage, a reduction in quality of life, a decrease in life expectancy Patient Hydroxyurea is a cytotoxin that raises fetal hemoglobin levels in some patients. It is the only disease rehabilitation therapy approved for sickle cell disease 4.

Sickle cells are characterized by hereditary hematologic diseases accounting for about 8% of African Americans. Individuals with sickle cell properties possess only one defective gene, unlike sickle cell disease, in which the patient has two genes causing abnormal hemoglobin production, usually with no health problems associated with sickle cell, normal Live a life. In rare cases, extreme symptoms such as severe dehydration symptoms or severe physical activity can cause serious health problems in patients with sickle cell characteristics including sudden death.